214 related articles for article (PubMed ID: 23935627)
1. Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression and Drug Resistance.
Jackson C; Browell D; Gautrey H; Tyson-Capper A
Int J Cell Biol; 2013; 2013():973584. PubMed ID: 23935627
[TBL] [Abstract][Full Text] [Related]
2. HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes.
Hart V; Gautrey H; Kirby J; Tyson-Capper A
Oncotarget; 2020 Nov; 11(46):4338-4357. PubMed ID: 33245725
[TBL] [Abstract][Full Text] [Related]
3. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
4. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.
He X; Ee PL; Coon JS; Beck WT
Clin Cancer Res; 2004 Jul; 10(14):4652-60. PubMed ID: 15269137
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the amplified Pip4k2beta gene from 17q11-12 in breast cancer cells confers proliferation advantage.
Luoh SW; Venkatesan N; Tripathi R
Oncogene; 2004 Feb; 23(7):1354-63. PubMed ID: 14691457
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
8. Intron-Encoded Domain of Herstatin, An Autoinhibitor of Human Epidermal Growth Factor Receptors, Is Intrinsically Disordered.
Tashiro D; Suetaka S; Sato N; Ooka K; Kunihara T; Kudo H; Inatomi J; Hayashi Y; Arai M
Front Mol Biosci; 2022; 9():862910. PubMed ID: 35573740
[TBL] [Abstract][Full Text] [Related]
9. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.
Di Modugno F; DeMonte L; Balsamo M; Bronzi G; Nicotra MR; Alessio M; Jager E; Condeelis JS; Santoni A; Natali PG; Nisticò P
Cancer Res; 2007 Mar; 67(6):2657-65. PubMed ID: 17363586
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
11. Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.
Gu L; Waliany S; Kane SE
PLoS One; 2009 Jul; 4(7):e6220. PubMed ID: 19593441
[TBL] [Abstract][Full Text] [Related]
12. Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis.
Qin C; Wilson C; Blancher C; Taylor M; Safe S; Harris AL
Clin Cancer Res; 2001 Apr; 7(4):818-23. PubMed ID: 11309328
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.
Shetty PK; Thamake SI; Biswas S; Johansson SL; Vishwanatha JK
PLoS One; 2012; 7(9):e44299. PubMed ID: 22957061
[TBL] [Abstract][Full Text] [Related]
14. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
15. [Herceptin therapy in breast cancer: new indication?].
Lebeau A
Verh Dtsch Ges Pathol; 2006; 90():99-106. PubMed ID: 17867585
[TBL] [Abstract][Full Text] [Related]
16. Alternative splicing of the human estrogen receptor alpha primary transcript: mechanisms of exon skipping.
Ferro P; Forlani A; Muselli M; Pfeffer U
Int J Mol Med; 2003 Sep; 12(3):355-63. PubMed ID: 12883652
[TBL] [Abstract][Full Text] [Related]
17. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).
Kim R; Tanabe K; Uchida Y; Osaki A; Toge T
Oncol Rep; 2002; 9(1):3-9. PubMed ID: 11748447
[TBL] [Abstract][Full Text] [Related]
18. Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention.
Uzor S; Zorzou P; Bowler E; Porazinski S; Wilson I; Ladomery M
Gene; 2018 Sep; 670():46-54. PubMed ID: 29802995
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia inducible factor 1alpha gene (HIF-1alpha) splice variants: potential prognostic biomarkers in breast cancer.
Dales JP; Beaufils N; Silvy M; Picard C; Pauly V; Pradel V; Formisano-Tréziny C; Bonnier P; Giusiano S; Charpin C; Gabert J
BMC Med; 2010 Jul; 8():44. PubMed ID: 20624301
[TBL] [Abstract][Full Text] [Related]
20. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
Azios NG; Romero FJ; Denton MC; Doherty JK; Clinton GM
Oncogene; 2001 Aug; 20(37):5199-209. PubMed ID: 11526509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
